Clinical Trial

An Open-label Single Center, Proof of Concept Study Evaluating the Efficacy of Roflumilast Foam 0.3% in Pediatric Patients With Non-Segmental Vitiligo (NSV)

Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated August 8, 2025 (before its estimated May 15, 2026 completion). Its status may not reflect the trial's current state.
Summary
An open-label single center, proof of concept study evaluating the efficacy of Roflumilast foam 0.3% in pediatric subjects with Non-Segmental Vitiligo (NSV)
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-07-29.
Status change: Not Yet Recruiting → Recruiting 2025-08-05
Trial Details
NCT Number NCT07105254
Lead Sponsor Derm Texas, PLLC
Collaborators: Arcutis Biotherapeutics, Inc.
Conditions Non-segmental Vitiligo
Enrollment 20 participants
Start Date 2025-08-01
Primary Completion 2026-05-15 (estimated)
Study Completion 2026-06-15 (estimated)
Updated on ClinicalTrials.gov 2025-08-08